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Background: Rotavirus is a common infectious cause of childhood hospitalisation in Hong Kong. Rotavirus
vaccines have been used in the private sector since licensure in 2006 but have not been incorporated in
the government’s universal Childhood Immunisation Programme. This study aimed to evaluate rotavirus
vaccine effectiveness against hospitalisation.
Methods: This case-control study was conducted in the 2014/2015 rotavirus season in six public hospi-
tals. Hospitalised acute gastroenteritis patients meeting inclusion criteria were recruited and copies of
their immunisation records were collected. Case-patients were defined as enrolled subjects with stool
specimens obtained in the first 48 h of hospitalisation that tested positive for rotavirus, whereas
control-patients were those with stool specimens obtained in the first 48 h of hospitalisation testing neg-
ative for rotavirus. Vaccine effectiveness for administration of at least one dose of either Rotarix

(GlaxoSmithKline Biologicals) or RotaTeq

(Merck Research Laboratories) was calculated as 1 minus
the odds ratio for rotavirus vaccination history for case-patients versus control-patients.
Results: Among the 525 eligible subjects recruited, immunisation records were seen in 404 (77%) subjects.
31% (162/525 and 126/404) tested positive for rotavirus. In the 404 subjects assessed for vaccine effective-
ness, 2.4% and 24% received at least 1 dose of either rotavirus vaccine in case- and control-patients
respectively. The unmatched vaccine effectiveness against hospitalisation for administration of at least
one dose of either rotavirus vaccines was 92% (95% confidence interval [CI]: 75%, 98%). The matched anal-
yses by age only and both age and admission date showed 96% (95% CI: 72%, 100%) and 89% (95% CI: 51%,
97%) protection against rotavirus hospitalisation respectively.
Conclusions: Rotavirus vaccine is highly effective in preventing hospitalisation from rotavirus disease in
young Hong Kong children.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Although rotavirus causes no, or very low, mortality in Hong
Kong, it does cause significant morbidity [1,2] and economic bur-
den [3]. There are two oral rotavirus vaccines available in Hong
Kong. Rotarix

(RV1, GlaxoSmithKline Biologicals) is a monovalent
live-attenuated human rotavirus vaccine given with a two-dose
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
(RV5, Merck
Research Laboratories) is a bovine-human reassortant pentavalent
rotavirus vaccine given with a three-dose schedule usually at 2, 4
and 6 months of age. In 2006, these vaccines were reported to be
safe and highly efficacious in the Americas and Europe [4,5], and
subsequently were shown to have about 96% efficacy against sev-
ere acute rotavirus gastroenteritis through 2 and 3 years of age in
Hong Kong, Singapore and Taiwan [6–8]. In 2013, the World Health
Organization re-confirmed its 2009 recommendation that rota-
virus vaccines be included in all National Immunisation Programs
(NIP) [9]. An economic evaluation from the Hong Kong govern-
ment’s perspective showed that inclusion of the vaccine in the uni-
versal Childhood Immunisation Programme (CIP) would be likely
cost-saving if the vaccine cost per course was less than USD
40–92 assuming a vaccine efficacy of 96% for preventing hospital-
isations and 89.5% for preventing outpatient visits [10]. This anal-
ysis did not include societal or wider economic benefits such as
herd protection [11], reduction of nosocomial infections [12] and
reduction of seizures [13]. Since 2012 the Hong Kong CIP offers
vaccines to all children at no cost to the families that protect
against 11 infectious diseases (Bacillus Calmette–Guérin,
hepatitis B, diphtheria, acellular pertussis, tetanus, inactivated
polio, 13-valent conjugate pneumococcus, measles, mumps,
rubella and varicella). Although both rotavirus vaccines have been
licensed in Hong Kong since 2006, they have not been included in
the CIP and have only been available in the private sector. This
non-universal use of rotavirus vaccine has allowed us to evaluate
rotavirus vaccine effectiveness in Hong Kong.2. Methodology
2.1. Subjects
During the 2014/2015 rotavirus season, we conducted a case-
control study to assess rotavirus vaccine effectiveness in acute gas-
troenteritis (AGE) patients admitted to public hospitals in Hong
Kong. During this period Hong Kong’s Hospital Authority managed
12 government funded public hospitals with general paediatric ser-
vices. These 12 hospitals were officially grouped into seven clusters.
This study was carried out in six public hospitals located from six
clusters: Kwong Wah Hospital, Prince of Wales Hospital, Queen
Elizabeth Hospital, Queen Mary Hospital, Tuen Mun Hospital and
United Christian Hospital. An estimated 71% of all inpatient paedi-
atric care in Hong Kong is provided by these public hospitals [14].
Although families from higher socioeconomic backgrounds are
more likely to use the private sector, public hospitals provide care
for all Hong Kong residents from all socioeconomic backgrounds.
AGE was defined as the occurrence of two or more episodes of
vomiting and/or three ormore episodes of diarrhoea (stools of a less
formed character than usual) within a 24-h period. Families of chil-
dren meeting the inclusion criteria were invited to participate in
the study. Inclusion criteria for selection of subjects included: (1)
admitted to one of the study hospitals for treatment of AGE during
the study period; (2) aged from 30 days to below 5 years; (3) onset
of diarrhoea or vomiting started less than or equal to 14 days before
admission; (4) normally receive vaccination and/or medical care in
Hong Kong; and (5) written informed consent obtained from par-
ents or guardians. Patients with parents or guardians unable to
speak Chinese (Cantonese or Mandarin) or English were excluded.
Research staff identified the potential AGE patients by looking up
the admission records of hospitalised childrenwith AGE symptoms.
However, since these records may not reflect the real diagnoses at
recruitment, some recruited patients were subsequently shown
not to have a diagnosis of AGE. Discharge summaries or case records
were reviewed independently by two of the authors and non-AGEpatients were excluded from the analysis. Subjects without stool
specimens known to be collected and tested for rotavirus within
the first 48 h of hospitalisation and subjects without copies of
immunisation records were excluded from the final analyses.
Rotavirus testing was performed on routinely collected stool
specimens from diarrhoea patients at five of the six study hospitals
(except Kwong Wah Hospital). During the study period, stool spec-
imens were collected from diarrhoea patients at Kwong Wah
Hospital and transported on ice for rotavirus testing with enzyme
immunoassay (EIA) at the Prince of Wales Hospital laboratory.
Specimens from four of the study hospitals were tested for
rotavirus by EIA and by reverse-transcriptase-polymerase chain
reaction (RT-PCR) at the remaining two sites (Appendix).
Case-patients were defined as AGE recruited subjects with stool
specimens obtained during the first 48 h of hospitalisation that
tested positive for rotavirus, whereas the control-patients were
AGE recruited subjects with stool specimens obtained within the
first 48 h of hospitalisation testing negative for rotavirus (i.e.
test-negative controls). Analyses were done using three groups of
controls: (1) matched with case-patients by date of birth
(±30 days) and date of admission (±30 days); (2) matched by date
of birth only; and (3) unmatched controls. The matched analyses
allowed for up to 5 control-patients to be matched to each
case-patient without replacement.2.2. Data collection
Parents or guardians of recruited patients were interviewed at
the study hospitals with a standardised questionnaire [15] modi-
fied for local use. Demographic information, birth and medical his-
tory were collected. Admission details, disease severity, final
diagnoses and laboratory results were obtained from patients’
medical records. Copies of subjects’ immunisation records were
obtained from their parents or guardians after interviews. If the
immunisation records were not available during the hospital
admission, verbal reports of vaccination history were collected
and copies of immunisation records were requested to be sent by
text message, e-mail, fax or post.2.3. Statistical analyses
Characteristics of case-patients and control-patients were com-
pared using chi-square tests and Wilcoxon rank-sum tests. Diar-
rhoea severity was examined by using the Vesikari score [16]
and other markers such as length of hospital stay and the use of
intravenous fluids. A dose of vaccine was considered relevant if it
was administered at least 14 days before admission. Patients were
regarded as fully vaccinated if they had received 2 doses of RV1 or
3 doses of RV5, whereas patients were regarded as partially vacci-
nated if they had received 1 dose of RV1 or 1–2 doses of RV5. For
the unmatched analysis, we used unconditional logistic regression,
adjusting for age on admission and month of admission, to obtain
the adjusted odds ratios (ORs) for rotavirus vaccination rate (at
least one dose and full series versus unvaccinated) among case-
patients compared with control-patients. Conditional logistic
regressions were used for matched analyses. We investigated rota-
virus vaccine effectiveness using each of the control groups. Vac-
cine effectiveness was calculated as (1 – OR)  100, where the
ORs were those obtained from the unconditional and conditional
logistic regressions. All analyses were performed using statistical
software R version 3.2.2 and SAS version 9.3 (SAS Institute, Cary,
NC). A two-tailed p-value of <0.05 was considered statistically
significant.
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Ethics approvals were granted by the Institutional Review
Boards of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster (Ref.: UW 14-508), Joint Chinese University of
Hong Kong – New Territories East Cluster Clinical Research Ethics
Committee (Ref.: CRE-2014.142), Kowloon West Cluster Research
Ethics Committee (Ref.: KW/EX-14-193(80-13)), New Territories
West Cluster Clinical & Research Ethics Committee (Ref.: NTWC/
CREC/1377/14), and Research Ethics Committee (Kowloon
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Fig. 1. Flow diagram showing enrolm3. Results
From 31 October 2014 to 23 April 2015 (covering the
2014/2015 rotavirus season in Hong Kong), there were a total of
2189 potential AGE patients listed in admission records, of which
573 (26%) were not approached by research staff (Fig. 1). Among
the 1616 subjects approached, 575 (36%) did not meet the initial
inclusion criteria screening, 129 (8%) refused to participate and
45 (3%) were discharged before consent could be obtained. Among
the 867 subjects enrolled in the study, 168 (19%) were subse-
quently found not to meet the inclusion criteria and 174 (20%)Not eligible 
n = 575 
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rotavirus within the first 48 h of hospitalisation. Among the 525
eligible subjects, 404 (77%) provided copies of immunisation
records and were included in the analyses assessing vaccine
effectiveness.
Patients without a rotavirus test result were not significantly
different from those who did have stool specimens collected and
tested in terms of gender, number of rooms for sleeping and num-
ber of other children aged under 10 years in the same household,
breastfeeding history, treatments given before admission (use of
antibiotics and oral rehydration solution), intravenous fluids dur-
ing hospital stay and rotavirus vaccination status. However, these
patients were older and more likely to have vomiting only during
the illness, had lower maximal body temperature and a shorter
length of hospital stay, and to have more highly educated parents
(Table 1). This reflected that stool specimens were not collected for
those recruited patients with vomiting only at admission and who
did not develop diarrhoea during the hospital admission. Although
there was no difference in rotavirus vaccination status betweenTable 1
Comparison of demographic characteristics, symptoms, severity, treatments and vaccinati
Had stool
tested for
(n = 525)
Background
Age on admission (months), median (range) 16 (1.2–6
Gender, n (%)
Male 294 (56)
Female 231 (44)
Number of rooms for sleeping in household, median (range) 2 (1–6)
Number of other children in household, median (range) 0 (0–5)
Parental highest educational level, n (%)
Junior secondary or below 77 (15)
Senior secondary 201 (38)
Matriculation or above 246 (47)
Ever breastfed, n (%) 415 (79)
Ever exclusively breastfed, n (%) 245 (60)
Month of admission, n (%)
October - November 2014 65 (12)
December 2014 101 (19)
January 2015 97 (19)
February 2015 99 (19)
March 2015 100 (19)
April 2015 63 (12)
Severity and symptoms
Length of hospital stay (days), median (range) 2.4 (0.3–2
Highest body temperature during illness (C), median (IQR) 38.7 (37.6
Vomiting only, n (%) 21 (4)
Diarrhoea only, n (%) 106 (20)
Diarrhoea and vomiting, n (%) 398 (76)
Diarrhoea severity on admission, n (%)#
Mild (Vesikari score: <7) 0(0)
Moderate (Vesikari score: 7–10) 44 (8)
Severe (Vesikari score: P11) 481 (92)
Treatments
Received antibiotics before admission, n (%) 84 (16)
Received oral rehydration solution before admission, n (%) 92 (18)
Received intravenous fluids during hospital stay, n (%) 279 (54)
Vaccination
Awareness of rotavirus vaccine before 6 months, n (%) 316 (61)
Ever received rotavirus vaccination, n (%) 70 (17)
Ever received RV1, n (%) 52 (14)
Ever received RV5, n (%) 18 (5)
Provided a copy of immunisation record, n (%) 404 (77)
IQR, interquartile range (lower quartile, upper quartile); RV1, Rotarix

(GlaxoSmithKline
* P-value < 0.05.
# Not all parameters of the Vesikari score were available for all patients, necessitating a
vomiting and diarrhoea from the discharge date and vomit/diarrhoea start date.these two groups, more guardians of patients with stool specimens
collected and tested were aware of rotavirus vaccine before their
child reached the age of six months (p-value = 0.04).
Among the 404 subjects with immunisation records seen that
were included in the analyses for vaccine effectiveness, stool spec-
imens of 126 (31%) subjects tested positive for rotavirus and 278
(69%) tested negative. 32% of rotavirus-positive patients were
admitted in January 2015, the peak of the 2014/15 rotavirus sea-
son. Compared to the rotavirus-negative patients, the rotavirus-
positive patients did not differ significantly with regard to gender,
number of rooms for sleeping and number of other children aged
under 10 years in the same household, treatments given before
admission (use of antibiotics and oral rehydration solution) and
highest body temperature during the illness (Table 2). However,
when compared with rotavirus-negative patients, the rotavirus-
positive patients were significantly older, had more severe illness
(longer length of hospital stay, higher Vesikari score and more
likely to receive intravenous fluids), were less likely to have ever
been breastfed or exclusively breastfed, to have parents with highon status between patients with and without stool specimens tested for rotavirus.
collected and
rotavirus
Did not have stool collected
and tested for rotavirus
P-value
(n = 174)
0) 31 (1–60) <0.0001*
0.3710
90 (52)
84 (48)
2 (1–4) 0.9581
0 (0–3) 0.7910
0.0477*
18 (10)
56 (32)
100 (57)
135 (78) 0.8275
74 (55) 0.3933
0.2624
23 (13)
30 (17)
45 (26)
35 (20)
25 (14)
30 (9)
3) 1.7 (0.5–63) <0.0001*
, 39.5) 37.9 (37.1, 39.1) <0.0001*
45 (26) <0.0001*
12 (7) <0.0001*
116 (67) 0.0302*
0.0836
0 (0)
23 (13)
151 (87)
25 (15) 0.6528
25 (15) 0.3639
92 (54) 1.0000
86 (52) 0.0428*
24 (20) 0.6198
21 (18) 0.3134
3 (3) 0.5305
121 (70) 0.0631
Biologicals); RV5, RotaTeq

(Merck Research Laboratories).
ssigning a minimal score of 1 for some missing variables and estimating durations of
Table 2
Comparison of demographic characteristics, symptoms, severity, treatments and vaccination status between rotavirus-positive and rotavirus-negative patients with
immunisation records seen (n = 404).
Rotavirus positive Rotavirus negative P-value
(n = 126) (n = 278)
Background
Age on admission (months), median (range) 20 (1.6–58) 13 (1.2–59) <0.0001*
Gender, n (%) 0.1994
Male 65 (52) 164 (59)
Female 61 (48) 114 (41)
Number of rooms for sleeping in household, median (range) 2 (1–6) 2 (1–5) 0.1696
Number of other children in household, median (range) 0 (0–3) 0 (0–5) 0.9807
Parental highest educational level, n (%) 0.0323*
Junior secondary or below 24 (19) 30 (11)
Senior secondary 52 (41) 106 (38)
Matriculation or above 50 (40) 141 (51)
Ever breastfed, n (%) 93 (74) 232 (84) 0.0333*
Ever exclusively breastfed, n (%) 44 (48) 154 (67) 0.0026*
Month of admission, n (%) <0.0001*
October - November 2014 5 (4) 51 (18)
December 2014 23 (18) 59 (21)
January 2015 40 (32) 30 (11)
February 2015 31 (25) 49 (18)
March 2015 19 (15) 50 (18)
April 2015 8 (6) 39 (14)
Severity and Symptoms
Length of hospital stay (days), median (range) 2.7 (1–23) 2.1 (0.3–15) 0.0002*
Highest body temperature during illness (C), median (IQR) 38.7 (38.2, 39.4) 38.6 (37.4, 39.5) 0.2035
Vomiting only, n (%) 1 (0.8) 11 (4) 0.1560
Diarrhoea only, n (%) 8 (6) 77 (28) <0.0001*
Diarrhoea and vomiting, n (%) 117 (93) 190 (68) <0.0001*
Diarrhoea severity on admission, n (%)# 0.0007*
Mild (Vesikari score: <7) 0 (0) 0 (0)
Moderate (Vesikari score: 7–10) 1 (0.8) 31 (11)
Severe (Vesikari score: P11) 125 (99) 247 (89)
Treatments
Received antibiotics before admission, n (%) 18 (15) 45 (16) 0.7622
Received oral rehydration solution before admission, n (%) 25 (21) 45 (17) 0.4206
Received intravenous fluids during hospital stay, n (%) 98 (78) 115 (42) <0.0001*
Vaccination
Awareness of rotavirus vaccine before 6 months, n (%) 66 (52) 189 (69) 0.0023*
Ever received rotavirus vaccination, n (%) 3 (2.4) 67 (24) <0.0001*
Ever received RV1, n (%) 1 (0.8) 51 (20) <0.0001*
Ever received RV5, n (%) 2 (1.6) 16 (7) 0.0472*
IQR, interquartile range (lower quartile, upper quartile); RV1, Rotarix

(GlaxoSmithKline Biologicals); RV5, RotaTeq

(Merck Research Laboratories).
* P-value < 0.05.
# Not all parameters of the Vesikari score were available for all patients, necessitating assigning a minimal score of 1 for some missing variables and estimating durations of
vomiting and diarrhoea from the discharge date and vomit/diarrhoea start date.
K.H.T. Yeung et al. / Vaccine 34 (2016) 4935–4942 4939educational level, and to have guardians who were aware of rota-
virus vaccine before 6 months old.
2.4% of the 126 rotavirus-positive patients were fully vaccinated
with rotavirus vaccines (1 subject received RV1 and 2 subjects
received RV5) and none were partially vaccinated. For rotavirus-
negative patients, 21% and 3.2% received full series (46 subjects
received RV1 and 12 subjects received RV5) and partial series (5
subjects received RV1 and 4 subjects received RV5) of rotavirus
vaccines respectively. Since the numbers of patients vaccinated
with specific vaccine types and partial series were insufficient to
provide meaningful subgroup analyses, we calculated vaccine
effectiveness by combining the numbers of patients vaccinated
with either brand and for either partial or full series of rotavirus
vaccination.
For the unmatched analyses of the 404 subjects with
immunisation records seen, the unadjusted vaccine effectiveness
for at least one dose of rotavirus vaccine was 92% (95% confidence
interval [CI]: 75%, 98%) (Table 3). The same results for vaccine
effectiveness were obtained after adjusting for patients’ age, both
with and without adjustments for month of admission (92% [95%
CI: 75%, 98%]).288 subjects could be matched by date of birth. 2.1% (2/97) of
these age-matched case-patients and 25% (48/191) of age-
matched control-patients were vaccinated with at least one dose
of rotavirus vaccine, giving a vaccine effectiveness of 96% (95%
CI: 72%, 100%). 214 subjects could be matched by both date of birth
and admission date. 2.5% (2/79) of these age- and admission date-
matched case-patients and 23% (31/135) of age- and admission
date-matched control-patients were vaccinated with at least one
dose of rotavirus vaccine, giving a vaccine effectiveness of 89%
(95% CI: 51%, 97%). We additionally calculated vaccine effective-
ness for full series rotavirus vaccination only, which was similar
to the combined full and partial series results (88–96% in matched
and unmatched analyses).
Analyses were also done on a restricted group of patients old
enough to be fully vaccinated with rotavirus vaccine (above
32 weeks). Similar vaccine effectiveness estimates were obtained
to the unrestricted models (data not shown). Vaccine effectiveness
of at least one dose of rotavirus vaccine has also been estimated for
different age groups below five by unmatched analyses with and
without adjustment and matched analyses. The unmatched and
unadjusted vaccine effectiveness were 88% (95% CI: 59%, 96%) over
Table 3
Vaccine effectiveness against rotavirus hospitalisation according to different approaches of analyses in 404 eligible subjects with immunisation records seen.
Received at least one dose Fully vaccinated
% (n/Total) VE (95% CI) (%) % (n/Total) VE (95% CI) (%)
Unconditional analyses
Cases 2.4% (3/126) 2.4% (3/126)
Controls 24% (67/278) 21% (58/278)
Unadjusted 92 (75, 98) 91 (70, 97)
Adjusted for age 92 (75, 98) 91 (69, 97)
Adjusted for age and month of admission 92 (75, 98) 91 (69, 97)
Conditional analyses
Matched by date of birth
Cases 2.1% (2/97) 2.1% (2/97)
Controls 25% (48/191) 96 (72, 100) 22% (42/191) 96 (70, 100)
Matched by date of birth and date of admission
Cases 2.5% (2/79) 2.5% (2/79)
Controls 23% (31/135) 89 (51, 97) 22% (29/135) 88 (48, 97)
VE, vaccine effectiveness; CI, confidence interval.
4940 K.H.T. Yeung et al. / Vaccine 34 (2016) 4935–4942the first two years of life, 90% (95% CI: 69%, 97%) over the first three
years of life and 92% (95% CI: 74%, 98%) over the first four years of
life (Table 4). The small sample size made it impossible to investi-
gate vaccine effectiveness stratified by exclusive breastfeeding his-
tory. However, unconditional and unadjusted vaccine effectiveness
for at least one dose of rotavirus vaccine in never breastfed and
ever breastfed groups were 91% (95% CI: 28%, 99%) and 93% (95%
CI: 70%, 98%) respectively.
4. Discussion
This is the first post-licensure evaluation on rotavirus vaccine
effectiveness in Hong Kong. Rotavirus vaccine of at least one dose
was highly effective and had 89%–96% ability to prevent hospital-
isation from rotavirus disease. Our findings are comparable to a
previous local clinical trial showing 92.6% vaccine efficacy of RV1
against rotavirus gastroenteritis requiring hospitalisation until
three years of age [8] and a Taiwanese study showing 90% (RV1)
and 97% (RV5) vaccine effectiveness post-vaccine introduction
[17]. A sample of studies from high income countries (Australia,
Belgium, Israel, Spain and the United States) using design similar
to ours have shown vaccine effectiveness ranging from 78% to
98% (Table 5).
In a local hospital-based surveillance study conducted from
2001 to 2003 [1], 30% of children admitted to hospital withTable 4
Vaccine effectiveness of at least one dose of rotavirus vaccine against rotavirus hospitalisa
seen.
62 years old
% (n/Total)# VE (95% CI) (
Unconditional analyses
Cases 3.9% (3/77)
Controls 25% (51/206)
Unadjusted 88 (59, 96)
Adjusted for age 88 (61, 97)
Adjusted for age and month of admission 88 (60, 97)
Conditional analyses
Matched by date of birth
Cases 3.5% (2/57)
Controls 24% (33/136) 94 (50, 99)
Matched by date of birth and date of admission
Cases 3.8% (2/52)
Controls 23% (23/100) 85 (32, 96.5)
VE, vaccine effectiveness; CI, confidence interval.
# % (n/Total) = proportion of subjects ever received rotavirus vaccine.diarrhoea, and stool specimens tested, were positive for rotavirus.
In our study, 31% of all gastroenteritis subjects with stool speci-
mens tested were positive for rotavirus. Although this proportion
of rotavirus diarrhoea is similar to that seen a decade ago it should
be noted that our study covered only the rotavirus season when
the proportion of rotavirus AGE would be expected to be higher.
Interestingly, a recent local study using hospital discharge data
from 1997 to 2011 showed no apparent decline in the incidence
of hospitalisation for rotavirus in children under the age of five fol-
lowing the availability of rotavirus vaccines in 2006 [2]. This may
have reflected a relatively low uptake of rotavirus vaccines within
the private sector in Hong Kong during these earlier post-licensure
years. In the present study, 17% of all subjects and 24% of the
rotavirus-negative subjects had received rotavirus vaccine through
the private sector. As noted above, countries that introduced
rotavirus vaccines into their NIPs, such as the United States and
Australia, have witnessed dramatic reductions in rotavirus (67–86%)
[18–20] and all-cause AGE (16–46%) [21,22] admissions. In Hong
Kong 9.8% of 824,514 children aged below five years and admitted
to the paediatric wards of public hospitals during the period 1 July
1997 to 31 March 2011 had a primary discharge diagnosis code
indicating a gastroenteritis-associated disorder [2]. The estimated
incidence rate of gastroenteritis (primary discharge diagnosis only)
was 3347 per 100,000 person-years. 1.6% of these 824,514 children
had either a primary or secondary discharge code of rotavirus,tion in children at different ages in 404 eligible subjects with immunisation records
63 years old 64 years old
%) % (n/Total)# VE (95% CI) (%) % (n/Total)# VE (95% CI) (%)
2.9% (3/102) 2.5% (3/118)
24% (58/241) 25% (64/261)
90 (69, 97) 92 (74, 98)
90 (68, 97) 92 (75, 98)
90 (68, 97) 92 (75, 98)
2.5% (2/79) 2.2% (2/93)
25% (40/162) 95 (63, 99) 25% (45/177) 96 (71, 100)
2.9% (2/69) 2.6% (2/77)
24% (29/123) 88 (48, 97) 23% (31/133) 89 (51, 97)
Table 5
Selected published studies of rotavirus vaccine effectiveness against hospitalisation in high income countries.
Article Location Sample size Vaccine
type
Vaccine
effectiveness
(95% CI) (%)
Dosage
completed
Adjustment
Field et al. [22] Australia 28 cases, 350 controls RV5 89 (76, 95) Full series –
Braeckman et al. [24] Belgium 215 cases, 276 controls RV1 and
RV5
91 (82, 95) At least one
dose
Matched by age
Muhsen et al. [25] Israel 111 cases, 216 controls RV1 and
RV5
89 (52, 98) At least one
dose
Matched by month and year of
birth
Martinon-Torres et al. [26] Spain 151 cases, 316 controls RV1 and
RV5
96 (86, 99) At least one
dose
–
Castilla et al. [27] Spain 756 cases, 6036 controls RV1 and
RV5
78 (70, 84) At least one
dose
Adjusted for age, sex, residence,
area, major risk conditions and
health care setting
Desai et al. [28] United
States
42 cases, 80 controls RV1 and
RV5
84 (24, 96) At least one
dose
Matched by age and admission
date
Boom et al. [29] United
States
79 cases, 108 controls RV5 89 (70, 96) Full series Adjusted for age
Staat et al. [30] United
States
40 cases, 49 controls RV5 95 (48, 99) Full series Matched by age and symptom-
onset date
Cortese et al. [31] United
States
140 cases, 280 controls RV5 92 (86, 96) Full series –
Payne et al. [32] United
States
RV1: 22 cases, 34 controls
RV5: 130 cases, 372 controls
RV1 and
RV5
RV1: 32 (156, 82)
RV5: 86 (74, 91)
– Adjusted for month and year of
birth, month and year of
symptom onset, and surveillance
site
Cortese et al. [33] United
States
RV1: 30 cases, 140 controls
RV5: 30 cases, 73 controls
RV1 and
RV5
RV1: 98 (90, 100)
RV5: 97 (77, 100)
Full series –
CI, confidence interval; RV1, Rotarix

(GlaxoSmithKline Biologicals); RV5, RotaTeq

(Merck Research Laboratories).
K.H.T. Yeung et al. / Vaccine 34 (2016) 4935–4942 4941equating to an incidence rate of rotavirus of 542 per 100,000
person-years. However after adjusting for likely under-coding
and under-testing of rotavirus the incidence rate for hospital
admission due to rotavirus was 1093 per 100,000 person-years.
Incorporation of rotavirus vaccine into the CIP could significantly
reduce the rotavirus hospitalisation rate of Hong Kong children.
This study has some limitations. First, there were 573 (26%)
potential AGE patients not approached by research staff and 45
(3%) patients approached but discharged before consent could be
obtained during the recruitment period. Potential differences
between the non-recruited and recruited subjects could affect
our estimates of vaccine effectiveness. No information was col-
lected for patients who were not approached but with verbal con-
sent some limited information was collected from guardians who
declined to participate. The latter group was not significantly dif-
ferent from the enrolled group with regard to age, gender, parental
educational level and verbal report on rotavirus vaccination status
but mothers were significantly older. However, maternal age was
not found to be a potential factor affecting estimates of vaccine
effectiveness. Second, AGE patients without a rotavirus test result
were found to be more likely to have vomiting only during the ill-
ness and had lower maximal body temperature and a shorter
length of hospital stay. This group of patients was more likely to
have been vaccinated with rotavirus vaccine. Since they were not
included in the analyses, our estimated vaccine effectiveness might
have been underestimated. Third, copies of immunisation records
were obtained for only 77% of the 525 eligible subjects. This
reduced the sample size for analyses of vaccine effectiveness. The
proportion of patients with stool tested rotavirus-positive and
guardians’ verbal report on rotavirus vaccination status were not
significantly different between those who provided and who did
not provide their immunisation records. However guardians of
patients who provided immunisation records were more likely to
report that they were aware of rotavirus vaccine before their chil-
dren were 6 months old. Analyses of vaccine effectiveness were
repeated for all 525 eligible subjects using the guardians’ verbal
report of rotavirus vaccination history and similar estimates ofeffectiveness were obtained to the models using data of the 404
subjects with immunisation records seen (data not shown). 98%
(397/404) of the immunisation records obtained confirmed the
guardians’ previous verbal report of rotavirus vaccination status.
This suggests that recall bias of rotavirus vaccination may be rela-
tively small and that verbal reports of rotavirus vaccination status
could be used in studies where obtaining confirmation of vaccina-
tion status is difficult. Fourth, since this was a relatively mild sea-
son, the number of potential AGE patients was small. The
government activated a serious response level (S2) alert because
of reports of H7N9 influenza in the vicinity. This required suspen-
sion of all research activities on infectious disease wards and hin-
dered recruitment during the period of 26 December 2014 to 15
January 2015 (peak of 2014/2015 rotavirus season) when 132
potentially eligible subjects could not be approached. Conse-
quently, our sample size was reduced resulting in less precise esti-
mates of vaccine effectiveness. Finally, use of RT-PCR to identify
rotavirus cases at two of the six study hospitals may have resulted
in detection of a low level of rotavirus in the stool that was not cau-
sally associated with AGE in these patients and thus underesti-
mated the vaccine effectiveness [23].
In conclusion, rotavirus vaccine is highly effective in preventing
rotavirus AGE hospitalisation. Incorporation of the vaccine into the
CIP could significantly reduce hospitalisations of Hong Kong chil-
dren aged below five years.Conflict of interest
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